Collaboration and Licensing Agreements - Narrative (Details) $ in Millions, ¥ in Billions	1 Months Ended				12 Months Ended				74 Months Ended
	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 JPY (¥)	Sep. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2022 USD ($) payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					$ 124,456,000		$ 52,158,000	$ 10,097,000
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					35,809,000		35,031,000	5,013,000
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					6,121,000		1,527,000	907,000
2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					30,000,000		35,000,000	5,000,000
2017 KKC Agreement | Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					6,100,000		1,500,000	900,000
Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					5,000,000		0	0
Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					0		0	0
Kyowa Kirin Co. Ltd | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees			$ 30,000,000
Potential development milestones			$ 55,000,000
Total revenues									$ 35,000,000
Potential commercialization milestones					60,300,000				60,300,000		¥ 8.5
Fee receivable for reduction in royalty rate																$ 40,000,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche																2
Kyowa Kirin Co. Ltd | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments												$ 30,000,000			$ 35,000,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments					8,000,000				8,000,000				$ 2,000,000
Upfront payment received		$ 12,000,000
Potential development and commercialization milestones					$ 113,000,000
Threshold percentage of net sales for tiered royalties					20.00%	20.00%
Fosun Pharma | Fosun Agreement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments										$ 3,000,000
Fosun Pharma | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					$ 5,000,000				5,000,000
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					700,000				700,000
Upfront payment received	$ 2,300,000
Potential development and commercialization milestones					16,700,000	$ 22.2
METiS Therapeutics Inc | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					800,000
Proceeds from milestone payments														$ 243,000,000
Upfront payment														$ 800,000
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue				10.00%
Percentage of non royalty revenue				20.00%
Maximum potential payment per agreement				$ 75,000,000
Aggregate cost of revenue recognized					27,600,000				$ 27,600,000
Total cost of goods sold					$ 12,400,000		$ 3,600,000	$ 1,000,000